Trial Type: Myeloma

Relapsed/refractory MM phase 3 trial comparing carfilzomib with dex vs carfilzomib with mezigdomide (Cel Mod) with dex. Please let me know if you have any patients who are refractory to Imid and anti CD38 therapy.